ImmunoGen, Inc.

IMGN
Delayed Nasdaq - 04/03 10:00:00 pm
3.42USD
-1.44%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

Number of employees : 75 people.
Sales per Businesses
20182019
USD
(in Million)
%USD
(in Million)
%
Antibody-drug Conjugate Therapies 53.45100% 82.27100%
Sales per Regions
20182019
USD
(in Million)
%USD
(in Million)
%
United States 53.45100% 82.27100%
Managers
Name Title
Mark J. Enyedy President, Chief Executive Officer & Director
Stephen C. McCluski Chairman
David G. Foster Vice President-Finance
Anna Berkenblit Chief Medical Officer & Senior Vice President
Thomas Ryll Vice President-Technical Operations
Richard J. Wallace Independent Director
Mark Alan Goldberg Independent Director
Kristine Peterson Independent Director
Dean Jonathan Mitchell Independent Director
Stuart A. Arbuckle Independent Director
Shareholders
Name Equities %
Wellington Management Co. LLP 18,102,224 10.4%
Redmile Group LLC 14,639,960 8.40%
The Vanguard Group, Inc. 14,000,749 8.04%
Renaissance Technologies LLC 10,707,139 6.15%
ClearBridge Investments LLC 9,050,869 5.20%
Capital Research & Management Co. (Global Investors) 7,095,570 4.07%
SSgA Funds Management, Inc. 5,346,426 3.07%
BlackRock Fund Advisors 4,490,897 2.58%
PRIMECAP Management Co. 3,674,927 2.11%
Millennium Management LLC 2,969,579 1.70%
Company contact information
ImmunoGen, Inc.
830 Winter Street
Waltham, MA 02451-1477

Phone : +1.781.895.0600
Fax : +1.781.895.0610
Web : http://www.immunogen.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capi. (M$)
IMMUNOGEN, INC.-33.01%594
LONZA GROUP13.73%31 009
CELLTRION, INC.22.13%25 160
IQVIA HOLDINGS INC.-33.52%20 797
SEATTLE GENETICS, INC.1.97%19 875
INCYTE CORPORATION-11.74%15 874
GALAPAGOS-6.43%12 893
ALNYLAM PHARMACEUTICALS, INC.-8.12%12 308
MODERNA, INC.78.12%11 041
QIAGEN N.V.19.14%9 469
ICON PUBLIC LIMITED COMPANY-24.17%7 293
BIO-TECHNE CORPORATION-15.09%7 272
HANGZHOU TIGERMED CONSULTING CO.,LTD-1.46%6 779
IONIS PHARMACEUTICALS, INC.-19.70%6 582
ACADIA PHARMACEUTICALS INC.-4.72%6 563
PHARMARON BEIJING CO., LTD.3.00%6 405
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.-22.20%6 245
PPD, INC.0.00%6 208
PRA HEALTH SCIENCES, INC.-34.36%5 278
UNITED THERAPEUTICS CORPORATION5.29%4 161
SYNEOS HEALTH, INC.-42.30%4 109